Treating aged marmosets with 10β,17β-dihydroxyestra-1,4-dien-3-one (DHED) improves side effects elicited from a type of breast cancer treatment.

Black women experience disproportionately elevated risks of developing and dying from early-onset breast cancer. New research published by Wiley online in CANCER reveals the genes that are most likely to be mutated to contribute to these increased risks.

A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers. The research, published in Annals of Oncology, found that GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing cancer among non-diabetic patients who used the drugs for weight management, compared to those who relied on diet and exercise alone.

Damon Runyon has awarded Quantitative Biology Fellowships to three outstanding young scientists applying computational approaches to persistent biological questions. Their projects will use machine learning, spatialomics, advanced network modeling, and other technologies to better understand breast cancer risk, improve response to immunotherapies, and identify new chromosomal drivers of cancer. Each postdoctoral scientist will receive independent funding ($240,000 total) to train under the joint mentorship of an established computational scientist and a cancer biologist.

Women with abnormal mammograms often have to wait for weeks to find out whether they have breast cancer.

 

Now, researchers at UC San Francisco and UC Berkeley have found a way to help reduce the wait and the worry by using AI to quickly identify those who are most likely to have the disease. By triaging these patients, the AI-guided workflow takes women with abnormal scans through the diagnostic process — from imaging to evaluation and sometimes even biopsy — in a single day. 

About The Study: In this cohort study of patients with early breast cancer, prediagnostic statin use was not associated with higher survival; however, postdiagnostic statin use was associated with lower all-cause and breast cancer–specific mortality among patients with hormone receptor–positive intrinsic subtypes. These findings suggest that statin therapy may improve survival of patients with early hormone receptor–positive subtypes.